<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03549559</url>
  </required_header>
  <id_info>
    <org_study_id>1R01HL141563</org_study_id>
    <nct_id>NCT03549559</nct_id>
  </id_info>
  <brief_title>Imaging Histone Deacetylase in the Heart</brief_title>
  <official_title>Imaging of Histone Deacetylase in the Heart</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this PET-MR imaging trial is to evaluate 11C-Martinostat, a histone
      deacetylase targeted radioligand, in patients with aortic stenosis, individuals with
      diabetes, and healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Histone deacetylases (HDACs), a class of epigenetic enzymes, play an important role in the
      pathophysiology of heart failure, including development of left ventricular hypertrophy and
      myocardial fibrosis. Preclinical data demonstrate the importance of HDAC inhibition in
      attenuating these pathological processes and maintaining the integrity of the myocardium.
      However, the role of HDACs in the human heart, and the utility of HDAC inhibition remains
      unknown. Therefore, a noninvasive method to detect HDAC activity in the human heart in
      healthy individuals and patients with heart disease may be of major medical and public health
      value to help determine prognosis, direct therapy, and guide the development of novel
      therapies for heart failure. The investigators have recently developed a novel radiotracer,
      11C-Martinostat, which binds with high affinity to class I HDACs. The objective of this
      protocol is to assess the utility of 11C-Martinostat PET-MR to detect HDAC expression in the
      hearts of healthy individuals and patients with severe aortic stenosis or diabetes.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>11C-Martinostat Binding</measure>
    <time_frame>10-60 minutes post-injection</time_frame>
    <description>Comparison of regional HDAC activity as measured by standard uptake value ratio (SUVR) of 11C-Martinostat between patient subjects with aortic stenosis or diabetes and healthy volunteers</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Heart Failure With Normal Ejection Fraction</condition>
  <condition>Left Ventricular Hypertrophy</condition>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy subjects will receive an IV injection of 11C-Martinostat and undergo simultaneous PET-MRI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetes Patient Subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient subjects with diabetes will receive an IV injection of 11C-Martinostat and undergo simultaneous PET-MRI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aortic Stenosis Patient Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient subjects with aortic stenosis will receive an IV injection of 11C-Martinostat and undergo simultaneous PET-MRI before and after transcatheter valve replacement.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>11C-Martinostat</intervention_name>
    <description>Imaging probe for evaluating the activity of histone deacetylase in the heart</description>
    <arm_group_label>Aortic Stenosis Patient Subjects</arm_group_label>
    <arm_group_label>Diabetes Patient Subjects</arm_group_label>
    <arm_group_label>Healthy Subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PET-MRI</intervention_name>
    <description>Siemens PET-MR Scanner (Biograph MMR)</description>
    <arm_group_label>Aortic Stenosis Patient Subjects</arm_group_label>
    <arm_group_label>Diabetes Patient Subjects</arm_group_label>
    <arm_group_label>Healthy Subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Group 1: Healthy Volunteers (n = 30)

          -  Healthy adults with no known history of medical disease

          -  Age 18-85 years

          -  No history cardiovascular disease

          -  Ability to provide informed consent

        Group 2: Patients with Diabetes (n = 16)

          -  Age 18-85 years

          -  Diagnosis of diabetes

          -  Echocardiogram within last 12 months showing no evidence of left ventricular
             hypertrophy or hemodynamic findings consistent with heart failure with preserved
             ejection fraction

          -  Ability to provide informed consent

        Group 3: Patients with Aortic Stenosis (n = 50)

          -  Age 18-85 years

          -  Echocardiogram or cardiac MRI scan within last 12 months documenting left ventricular
             hypertrophy and degenerative calcific aortic stenosis

          -  Ability to provide informed consent

        Exclusion Criteria:

          -  Known contraindication to MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>David E Sosnovik, MD</last_name>
    <phone>617-724-3407</phone>
    <email>dsosnovik@mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne L Philip, MPH</last_name>
    <phone>617-726-0431</phone>
    <email>alphilip@mgh.harvard.edu</email>
  </overall_contact_backup>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>May 25, 2018</study_first_submitted>
  <study_first_submitted_qc>May 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2018</study_first_posted>
  <last_update_submitted>June 11, 2018</last_update_submitted>
  <last_update_submitted_qc>June 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>David E Sosnovik</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Hypertrophy, Left Ventricular</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

